<DOC>
	<DOCNO>NCT01158599</DOCNO>
	<brief_summary>This open-label , uncontrolled phase 4 study ass safety immunogenicity Japanese encephalitis ( JE ) vaccine Ixiaro® ( IC51 ) elderly population .</brief_summary>
	<brief_title>This Study Assess Safety Immunogenicity Ixiaro® ( IC51 ) Elderly Population</brief_title>
	<detailed_description />
	<mesh_term>Encephalitis</mesh_term>
	<mesh_term>Encephalitis , Japanese</mesh_term>
	<criteria>Male female subject ≥ 65 year age time 1st vaccination good general health status include subject pharmacologically control condition like hypercholesterolemia , hypertension , cardiovascular disease non insulindependent diabetes mellitus Weight : ≥ 45.5 kg ≤ 150 kg Visit 0 ( Screening Visit ) White blood cell ≥2,500/mm3 &lt; 11,000/mm3 Visit 0 Absolute neutrophil count within normal limit Visit 0 Platelets within normal limit Visit 0 Written inform consent obtain subject prior study related procedure History clinical manifestation flavivirus infection ( Yellow Fever , Dengue Fever , JE , Tick Borne Encephalitis ( TBE ) West Nile Fever/Neuroinvasive Disease ) Vaccination JE ( include study participation previous current IC51/IXIARO® clinical study ) , Yellow fever , Dengue Fever West Nile Fever time prior study Vaccination TBE within 30 day prior first IXIARO® vaccination Visit 1 ( Day 0 ) Visit 3 ( Day 70 ) Use investigational nonregistered medicinal product within 30 day prior IXIARO® vaccination Visit 1 ( Day 0 ) throughout entire study period Immunodeficiency include status postorgantransplantation immunosuppressive therapy , family history congenital hereditary immunodeficiency Infection human immunodeficiency virus ( HIV , negative test result within 30 day screen acceptable ) , Hepatitis B virus ( HBV , Hepatitis B surface antigen [ HBsAg ] ) Hepatitis C virus ( HCV ) Administration chronic ( define longer 14 day ) immunosuppressant immunemodifying drug within 30 day prior IXIARO® vaccination Visit 1 ( Day 0 ) study Visit 3 ( Day 70 ) . ( For corticosteroid mean prednisone equivalent &gt; = 0.05 mg/kg/day ; topical inhale steroid allow ) . Periodic steroid injection , e.g. , intraarticular , allow within 30 day prior first IXIARO® vaccination Visit 1 ( Day 0 ) Visit 3 ( Day 70 ) History autoimmune disease , include Type I Diabetes mellitus . Subjects vitiligo thyroid disease take thyroid hormone replacement exclude . Acute febrile infection exacerbation chronic infection day IXIARO® vaccination ( Day 0 Day 28 ) Skin cancer past six month . If treatment skin cancer successfully complete six month ago malignancy consider cure , subject may enrol . Subjects history skin cancer must vaccinate previous site malignancy . Any malignancy past 5 year . If treatment cancer successfully complete 5 year ago malignancy consider cure , subject may enrol . Clinically significant hematological , renal , hepatic , pulmonary , central nervous , cardiovascular gastrointestinal disorder , adequately control medical treatment within last 12 week IXIARO® vaccination Visit 1 ( Day 0 ) judge site 's Principal Investigator Clinically significant mental disorder adequately control medical treatment History GuillainBarréSyndrome ( GBS ) . History severe hypersensitivity reaction , particular component IXIARO® vaccine ( e.g . protamine sulfate ) , anaphylaxis severe case atopy require emergency treatment hospital admission History urticaria hymenoptera envenomation , drug , physical provocation , idiopathic cause Drug addiction within 6 month prior Visit 0 throughout entire study period ( include alcohol dependence , i.e . approximately 60 g alcohol per day , condition might interfere study conduct ) Inability unwillingness avoid usual intake alcohol ( &gt; 60 g alcohol/day ) 48 hour vaccination Any condition might interfere study objective would limit subject 's ability complete study opinion investigator Persons commit institution ( virtue order issue either judicial administrative authority ) participate study</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Japanese Encephalitis</keyword>
	<keyword>Vaccination</keyword>
	<keyword>Ixiaro</keyword>
	<keyword>elderly population</keyword>
</DOC>